Design and development of novel EGFR inhibitors spanning all subgroups of EGFR mutations in non-small cell lung cancer

The Innovation 2026 Open access

Read full text
Authors: Caolin Wang, Yiting Cen, Manzhan Zhang, Jiahong Tang, Zitong Yan, Lijuan Xie, Deheng Sun, Wei Zhou, Jie Wang, Panpan Yu, Zhen Yuan, Junyi Wang
+8 more Zeyan Hu, Tingyuan Yang, Wenjie Sha, Shiliang Li, Zhenjiang Zhao, Yufang Xu, Zhuo Job Chen, Honglin Li
DOI: 10.1016/j.xinn.2026.101313
Cited by: 0
References: 64

Abstract

as a promising pan-EGFR inhibitor, currently in phase 1 clinical trials (CTR20212743).

Fields of Study & Subjects

Lung Cancer Treatments and Mutations HER2/EGFR in Cancer Research Synthesis and biological activity

Publication details

Journal / source
The Innovation
Volume
7
Issue
7
Pages
101313–101313
Publication date
12 February 2026
Language
EN